Muge Celiktas
Muge Celiktas
The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Stability of the hybrid epithelial/mesenchymal phenotype
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ...
Oncotarget 7 (19), 27067, 2016
2852016
Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival
MJ Schliekelman, A Taguchi, J Zhu, X Dai, J Rodriguez, M Celiktas, ...
Cancer research 75 (9), 1789-1800, 2015
1482015
Metastatic progression of prostate cancer and e-cadherin: Regulation by Zeb1 and Src family kinases
AP Putzke, AP Ventura, AM Bailey, C Akture, J Opoku-Ansah, M Çeliktaş, ...
The American journal of pathology 179 (1), 400-410, 2011
1372011
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome
SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ...
Proceedings of the National Academy of Sciences 113 (11), E1555-E1564, 2016
1192016
MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway
SC Tripathi, JF Fahrmann, M Celiktas, M Aguilar, KD Marini, MK Jolly, ...
Cancer research 77 (16), 4414-4425, 2017
592017
Distinguishing mechanisms underlying EMT tristability
D Jia, MK Jolly, SC Tripathi, P Den Hollander, B Huang, M Lu, M Celiktas, ...
Cancer convergence 1 (1), 1-19, 2017
552017
Role of CPS1 in cell growth, metabolism, and prognosis in LKB1-inactivated lung adenocarcinoma
M Çeliktaş, I Tanaka, S Chandra Tripathi, JF Fahrmann, ...
JNCI: Journal of the National Cancer Institute 109 (3), 2017
402017
A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets
A Taguchi, AD Taylor, J Rodriguez, M Çeliktaş, H Liu, X Ma, Q Zhang, ...
Cancer research 74 (17), 4694-4705, 2014
322014
Proteomic signatures associated with p53 mutational status in lung adenocarcinoma
A Taguchi, O Delgado, M Çeliktaş, H Katayama, H Wang, AF Gazdar, ...
Proteomics 14 (23-24), 2750-2759, 2014
202014
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7: 27067–84
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ...
8
Distinguishing mechanisms underlying EMT tristability. Cancer Converg. 2017
D Jia, MK Jolly, SC Tripathi, P Den Hollander, B Huang, M Lu, M Celiktas
6
Stability of the hybrid epithelial/mesenchymal phenotype, Oncotarget (2016)
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash
5
Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7 (19): 27067–84
MK Jolly, SC Tripathi, D Jia, SM Mooney, M Celiktas, SM Hanash, ...
PubMed Abstract| Publisher Full Text| Free Full Text| F1000 Recommendation, 0
5
CES2 Expression in pancreatic adenocarcinoma is predictive of response to irinotecan and is associated with type 2 diabetes
M Capello, JF Fahrmann, MV Rios Perez, JV Vykoukal, E Irajizad, ...
JCO Precision Oncology 4, 426-436, 2020
22020
Stability and stemness of the hybrid epithelial-mesenchymal phenotype
MK Jolly, D Jia, SC Tripathi, S Mooney, M Celiktas, SM Hanash, SA Mani, ...
Cancer Research 77 (13 Supplement), 3053-3053, 2017
12017
Loss of immunoproteasome driven by EMT is associated with immune evasion and poor prognosis in non-small cell lung cancer
SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ...
Journal of Thoracic Oncology 11 (2), S48-S49, 2016
12016
A novel MTA non-competitive PRMT5 inhibitor
R Malik, PK Park, CM Barbieri, Y Blat, S Sheriff, CA Weigelt, LM Kopcho, ...
Cancer Research 81 (13 Supplement), 1140-1140, 2021
2021
Aberrant tryptophan catabolism marked by high kynureninase expression contributes to immunosuppression and poor outcome in lung adenocarcinoma
EJ Ostrin, JF Fahrmann, I Tanaka, M Celiktas, C Aguilar, M Aguilar, ...
Cancer Research 78 (13 Supplement), 1447-1447, 2018
2018
MCAM modulates small cell lung cancer chemoresistance via PI3k/Akt/Sox2 signaling pathway
SC Tripathi, JF Fahrmann, M Celiktas, M Aguilar, KD Marini, MK Jolly, ...
Cancer Research 77 (13 Supplement), 3170-3170, 2017
2017
CPS1 as a therapeutic target and prognostic indicator in LKB1-inactivated lung adenocarcinoma
M Celiktas, I Tanaka, SC Tripathi, JF Fahrmann, C Aguilar-Bonavides, ...
Cancer Research 77 (13 Supplement), 2775-2775, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20